InvestorsHub Logo
Followers 54
Posts 1832
Boards Moderated 0
Alias Born 03/22/2015

Re: DR Ryan post# 353889

Sunday, 04/11/2021 1:39:48 PM

Sunday, April 11, 2021 1:39:48 PM

Post# of 414020

Oh but don't you see n2k...if Nasrat would have just been selling these opioids the whole time Elite would've made $100 million in revenue by now and we'd all be rich. We definitely wouldn't have been sued and gone under.

Hope I don't need the sarcasm button for this one. ;)








Where this post fails in sarcasm, it succeeds in irony. The sad fact is that had Norco and Percocet been commercialized in a timely fashion, we very well could have $100 million in revenue by now. Likewise, it is extremely unlikely Elite would have been sued, just like every other small to mid-size generic pharma who continue to manufacture and sell opioid products in a highly-regulated market.



https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157514121

no2koolaid Monday, 08/10/20 04:53:54 PM
Post # 341031 of 351823

Percocet: 16 competitors with equal prorated market share of 6.25%/500 = 31.250 M
Norco: 11 competitors with equal prorated market share of 0.91% / 447 = 40.680 M
Ty w/code: 8 competitors with equal prorated market share of 12.5% / 45 = 5.630 M
Methadone: 10 competitors with equal prorated market share of = 10.0% / 30 = 3.00 M
Hydromorphone: 8 competitors with equal prorated market share of = 12.5% / 30 = 3.750 M

In aggregate, the prorated market share for an owner of the drugs at peak would be more than $50M, it would be = $84.310 M.







Occam's razor: the simplest solution is most likely the right one.

Hanlon's razor: never attribute to malice that which is adequately explained by stupidity.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News